HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In Vivo.
HPMA
cancer therapy
controlled drug release
drug delivery
mebendazole
polymer
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
04 Jun 2022
04 Jun 2022
Historique:
received:
17
05
2022
revised:
30
05
2022
accepted:
02
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Mebendazole and other benzimidazole antihelmintics, such as albendazole, fenbendazole, or flubendazole, have been shown to possess antitumour activity, primarily due to their microtubule-disrupting activity. However, the extremely poor water-solubility of mebendazole and other benzimidazoles, resulting in very low bioavailability, is a serious drawback of this class of drugs. Thus, the investigation of their antitumour potential has been limited so far to administering repeated high doses given peroral (p.o.) or to using formulations, such as liposomes. Herein, we report a fully biocompatible, water-soluble, HPMA copolymer-based conjugate bearing mebendazole (P-MBZ; M
Identifiants
pubmed: 35745774
pii: pharmaceutics14061201
doi: 10.3390/pharmaceutics14061201
pmc: PMC9229042
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Czech Science Foundation
ID : 19-05649S
Organisme : Institutional Research Concept RVO
ID : 61388971
Organisme : Ministry of Education, Youth, and Sports of the Czech Republic within the Interexcellence program
ID : LTAUSA18083
Organisme : Academy of Sciences of Czech Republic
ID : JSPS-22-01
Références
J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
Br J Clin Pharmacol. 1985 Jan;19(1):79-86
pubmed: 3978023
J Control Release. 2021 Apr 10;332:563-580
pubmed: 33722611
Mol Cancer Ther. 2002 Nov;1(13):1201-9
pubmed: 12479701
Toxicol In Vitro. 2015 Dec;29(8):2038-44
pubmed: 26315676
Sci Rep. 2018 Aug 9;8(1):11926
pubmed: 30093705
Br J Cancer. 2020 Feb;122(4):517-527
pubmed: 31844184
Oncotarget. 2017 Feb 21;8(8):12576-12595
pubmed: 28157711
J Control Release. 2003 Feb 21;87(1-3):33-47
pubmed: 12618021
Immunopharmacol Immunotoxicol. 2017 Aug;39(4):199-210
pubmed: 28472897
Br J Clin Pharmacol. 1982 Sep;14(3):453-5
pubmed: 7126419
Bioconjug Chem. 2010 May 19;21(5):797-802
pubmed: 20397686
Oncotarget. 2017 Feb 21;8(8):12968-12982
pubmed: 28099902
Adv Drug Deliv Rev. 2009 Nov 12;61(13):1131-48
pubmed: 19699249
BMC Res Notes. 2019 Apr 22;12(1):234
pubmed: 31010428
Neuro Oncol. 2011 Sep;13(9):974-82
pubmed: 21764822
Polymers (Basel). 2021 Jul 30;13(15):
pubmed: 34372133
Adv Drug Deliv Rev. 2013 Jan;65(1):49-59
pubmed: 23123294
Mol Cancer Res. 2008 Aug;6(8):1308-15
pubmed: 18667591
Pharmacol Ther. 2006 Dec;112(3):630-48
pubmed: 16815554
J Immunol. 2009 Oct 15;183(8):4904-12
pubmed: 19801515
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1571-6
pubmed: 25605897
Toxicol In Vitro. 2017 Sep;43:87-91
pubmed: 28606429
Biomol Ther (Seoul). 2019 Jan 31;27(1):117-125
pubmed: 30642153
Pharmaceutics. 2021 Jan 28;13(2):
pubmed: 33525658
Oncotarget. 2016 Oct 18;7(42):68571-68584
pubmed: 27612418
J Control Release. 2012 Dec 28;164(3):346-54
pubmed: 22759979
Molecules. 2008 Mar 03;13(3):519-47
pubmed: 18463563
J Photochem Photobiol B. 2016 Feb;155:1-6
pubmed: 26709667
Oncotarget. 2015 Mar 20;6(8):6326-40
pubmed: 25811972
Anticancer Res. 2009 Oct;29(10):3791-6
pubmed: 19846910
Clin Cancer Res. 2002 Sep;8(9):2963-9
pubmed: 12231542
Acta Biomater. 2021 Jan 1;119:349-359
pubmed: 33186784